Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib as adjuvant therapy after curative treatment for hepatocellular carcinoma
CTR20131653Phase 3Completed
- Sponsor
- Bayer
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sorafenib in hepatocellular carcinoma (HCC), sponsored by Bayer. Started May 2014; status: completed.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20131653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131653.